Back to top
more

BioXcel Therapeutics (BTAI)

(Real Time Quote from BATS)

$1.11 USD

1.11
1,065,036

+0.02 (1.84%)

Updated Apr 8, 2026 03:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (143 out of 243)

Industry: Medical - Biomedical and Genetics

Brokerage Reports

Research for BTAI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

BioXcel Therapeutics, Inc. [BTAI]

Reports for Purchase

Showing records 101 - 120 ( 126 total )

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 101

06/05/2019

Company Report

Pages: 5

Multiple Regulatory Milestones Achieved; Pipeline Progressing Rapidly; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 102

05/28/2019

Company Report

Pages: 5

1Q19 Financial Results Reported; R-D Day Event Showcases BXCL501 Development Scope; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 103

05/06/2019

Company Report

Pages: 5

BXCL501 Thin Film Formulation Process Development; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 104

03/26/2019

Company Report

Pages: 5

Positive AVP-786 Pivotal Data Draws Attention to BXCL501 in Alzheimer''s Disease-Related Agitation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 105

03/11/2019

Company Report

Pages: 4

2018 Financial Results Reported; Anticipating Further Clinical Progress in 2019; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 106

03/05/2019

Company Report

Pages: 5

Established Pharma Firms Join the Party; Triplet Regimen Slated for Assessment in Pancreatic Cancer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 107

02/05/2019

Company Report

Pages: 6

Further Proof-of-Concept Data in Opioid Withdrawal; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 108

01/04/2019

Company Report

Pages: 5

Positive Proof-of-Concept Achieved in Alzheimer''s Patients; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 109

12/12/2018

Company Report

Pages: 4

BXCL501 Investigational New Drug Application Accepted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 110

12/05/2018

Company Report

Pages: 4

BXCL501 Proof-of-Concept Established; Healthy Cash Runway; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 111

10/31/2018

Company Report

Pages: 4

Poster Presentation at Upcoming Medical Meeting Announced; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 112

10/30/2018

Company Report

Pages: 4

BXCL501 Slated to Advance Into Clinical Testing Near-Term; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 113

10/08/2018

Company Report

Pages: 4

First BXCL701 Investigational New Drug Filing Submitted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 114

09/25/2018

Company Report

Pages: 4

Immuno-Oncology Partnership Expanded Into Clinical Development; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 115

09/19/2018

Company Report

Pages: 4

Translational Medicine, Clinical Pharmacology and Regulatory Affairs Head Appointed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Unclassified

Record: 116

09/05/2018

Company Report

Pages: 4

Head of Global Pharmaceutical Development and Operations Appointed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Unclassified

Record: 117

08/27/2018

Company Report

Pages: 5

Immuno-Oncology Clinical Advisory Board Established; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Unclassified

Record: 118

08/09/2018

Company Report

Pages: 4

2Q18 Financial Results Reported; Significantly Lower-Than-Projected Spending; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Unclassified

Record: 119

08/01/2018

Company Report

Pages: 5

Business Development Head Appointed; Clinical Trial Milestones Approaching; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Unclassified

Record: 120

07/25/2018

Company Report

Pages: 5

BXCL701 Principal Mechanism Highlighted in Peer-Reviewed Publication; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party